Evidence map›Paper›PMID 35980834›Full record

ArticlePreventing chronic disease2022

Polypharmacy and Health-Related Quality of Life/Psychological Distress Among Patients With Chronic Disease.

Lisa Van Wilder, Brecht Devleesschauwer, Els Clays, Peter Pype, Sophie Vandepitte, Delphine De Smedt

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Preventing chronic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Health-related quality of life among older adults following acute hospitalization: longitudinal analysis of a randomized controlled trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lisa Van WilderDepartment of Public Health and Primary Care, Ghent University, University Hospital, Corneel Heymanslaan 10 4K3, 9000 Ghent, Belgium. Email: lisa.vanwilder@ugent.be.
Brecht DevleesschauwerDepartment of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
Els ClaysDepartment of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Peter PypeDepartment of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Sophie VandepitteDepartment of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Delphine De SmedtDepartment of Public Health and Primary Care, Ghent University, Ghent, Belgium.
Ghent University · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo date, no study has investigated the impact of polypharmacy (use of ≥5 medications concurrently) on health-related quality of life (HRQOL) and psychological distress in a combined sample of chronic disease patients and patients with multimorbidity, using diverse HRQOL measures. This study aimed to explore the association between polypharmacy and HRQOL/psychological distress by using data from a cross-sectional study in Flanders (Belgium).

methodsWe analyzed cross-sectional survey data on 544 chronically ill patients recruited from June 2019 through June 2021. HRQOL was measured with the EuroQol-5 Dimension-5 Level questionnaire (EQ-5D-5L) and the 12-Item Short Form Health Survey (SF-12); psychological distress was measured with the Hospital Anxiety and Depression Scale (HADS). Multiple linear regression models were built to assess the association between polypharmacy and HRQOL/psychological distress.

resultsOverall, compared with patients without polypharmacy, patients with polypharmacy reported worse EQ-5D-5L index values, EuroQol visual analogue scale (EQ-VAS) scores, SF-12 physical component scores (PCS), SF-12 mental component scores (MCS), and HADS anxiety and depression subscales. In the final regression model adjusting for age, sex, educational attainment, and multimorbidity, polypharmacy remained significantly associated with lower HRQOL in terms of the EQ-5D-5L index (β = -0.12; P = .008), EQ-VAS (β = -0.11; P = .01), and SF-12 PCS (β = -0.15; P = .002) but not with psychological distress (HADS) and SF-12 MCS.

conclusionThis study found that polypharmacy was negatively associated with the physical domain of HRQOL, but not with the mental domain, among patients with chronic diseases. These results may be especially important for patients with multimorbidity, given their greater risk of polypharmacy.

Indexed as

Psychological DistressQuality of LifeChronic DiseaseCross-Sectional StudiesHumansPolypharmacySurveys and Questionnaires

Identifiers

PMID35980834
PMCPMC9390791
OpenAlexW4291820652

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.